The drug in question is adalimumab, a fully human monoclonal antibody that neutralises tumour necrosis factor alpha, or TNFα, a cytokine central to the inflammatory cascade that drives retinal tissue damage in uveitis by promoting mononuclear cell trafficking into ocular tissues. Adalimumab is the only non-corticosteroid drug licensed for immune-mediated non-infectious uveitis, and its efficacy was established in the landmark VISUAL I and VISUAL II trials, which showed that it delayed treatment failure in patients with active disease and in those with inactive but steroid-dependent disease. Yet those trials had design limitations with real-world consequences: they did not test adalimumab as an add-on to standard therapy, the most common clinical scenario when first-line agents fail; they excluded cystoid macular oedema, the leading cause of uveitis-related visual loss, from both inclusion and treatment-failure criteria; and they required high levels of vitreous inflammation for enrolment. Those restrictions translated into restrictive access criteria worldwide, including a recommendation from the UK’s National Institute for Health and Care Excellence that bars patients with unilateral disease without systemic inflammation, steroid-dependent inactive uveitis, or those new to standard immunosuppressive therapy.

The new study, called ASTUTE, was designed specifically to close those evidence gaps. Conducted at 18 NHS tertiary ophthalmology departments across the United Kingdom, it was a multi-centre, parallel-group, placebo-controlled randomised trial with an unusual twist: a 16-week treatment run-in before randomisation. All participants first received open-label adalimumab, delivered as fortnightly subcutaneous 40-milligram injections of a licensed biosimilar, Imraldi, while their oral prednisolone was tapered toward 5 milligrams per day or less, with the rate of reduction guided by disease activity and clinician judgement rather than a fixed schedule. Only participants who responded, defined as achieving prednisolone at or below 5 milligrams per day with no sign of active disease, were then randomised to continue adalimumab or switch to an identical placebo pen containing all excipients but no active drug. This enriched enrolment, randomised withdrawal design, more often seen in industry-sponsored analgesia trials, served two purposes: it ensured the drug was only continued in patients in whom it was demonstrably working, and it provided an objective, biomarker-free criterion for stopping treatment, something absent from routine clinical practice.

The trial’s eligibility criteria were deliberately broad. Patients aged 18 or over could enter the run-in if they had active sight-threatening uveitis, marked by inflammatory chorioretinal lesions, central macular thickness above 320 microns, retinal vasculitis or vitreous haze greater than 0.5, and were taking more than 5 milligrams per day of oral prednisolone; or if they had controlled disease that still required more than 5 milligrams per day of prednisolone alongside conventional immunomodulatory drugs. Concomitant immunosuppression such as mycophenolate mofetil, methotrexate, azathioprine, ciclosporin or tacrolimus was permitted and recorded throughout. The result was a study population far more diverse than those in previous trials, spanning intermediate, posterior and panuveitis, with birdshot retinochoroiditis the single most common diagnosis, and including patients with cystoid macular oedema and mild to moderate vitreous inflammation who would previously have been turned away.

Between July 2021 and June 2024, 323 patients were screened, 202 enrolled in the treatment run-in, and 119, or 65.4 percent, responded well enough to be randomised. After four withdrawals, 115 participants entered the randomised phase, 60 receiving adalimumab and 55 placebo. The primary outcome was time to the first treatment failure, a composite endpoint capturing any of six signs of reactivated disease: a drop of 15 or more letters in best-corrected visual acuity on ETDRS charts, new active chorioretinal lesions, a greater than 20 percent increase in central macular thickness on optical coherence tomography, onset or worsening of retinal vasculitis on fluorescein angiography, a two-step worsening of vitreous haze on the Standardization of Uveitis Nomenclature scale, or the need for prednisolone above 5 milligrams per day to maintain disease control. Topical steroids were allowed for anterior chamber activity, a pragmatic choice reflecting that isolated flare manageable with drops would not prompt withdrawal of a biologic in practice, while escalation to oral prednisolone was counted as failure.

The results were striking. At 12 months, an estimated 31.4 percent of participants on adalimumab had experienced treatment failure, compared with 59.0 percent on placebo, a hazard ratio of 0.42 with a 95 percent confidence interval of 0.23 to 0.75 and a p-value of 0.003. In other words, adalimumab cut the hazard of treatment failure by more than half. The most frequently observed component of failure was the prescription of higher-dose prednisolone to maintain remission, underscoring how much of the drug’s benefit lies in enabling genuine corticosteroid sparing, an outcome patients strongly prefer given the substantial toxicity of long-term steroids. Adherence was high, with more than 90 percent of scheduled injections received in both groups, and a per-protocol sensitivity analysis produced nearly identical results.

Perhaps the most consequential finding came from a pre-specified subgroup analysis. Of the 115 randomised participants, 98, roughly 85 percent, would have been ineligible for adalimumab under the current NICE technology appraisal, whether because of steroid-dependent inactive disease, unilateral isolated uveitis, mild to moderate vitreous inflammation, macular oedema alone, or being new to standard immunosuppression. Yet these patients benefited at least as much as those who met the eligibility criteria: 30.0 percent of the NICE-ineligible group on adalimumab experienced treatment failure at 12 months versus 60.0 percent on placebo, a hazard ratio of 0.37. The benefit seen in this broader population was also of a similar magnitude to that reported in the VISUAL trials, and the biosimilar used reflects a class effect of adalimumab rather than a property of any single branded product.

Secondary outcomes painted a broadly favourable but nuanced picture. Patient-reported visual function improved more with adalimumab than placebo, with a statistically significant difference emerging after week 48; at week 80 the geometric mean ratio was 0.56, where a lower score indicates better vision-related quality of life. Other measures, including the EQ-5D utility score, visual acuity and central macular thickness, showed point estimates favouring adalimumab that did not reach statistical significance, a difficulty the investigators attribute to the fact that participants were not followed in the trial after treatment failure, so between-group comparisons drew predominantly on patients still in remission. Safety data were reassuring across two years: adverse event rates were actually lower on adalimumab than placebo for both infections and infestations, at 47.9 versus 73.2 per 100 person-years, and skin disorders, at 8.5 versus 11.7 per 100 person-years, though neither difference was statistically significant. There were no deaths and no suspected unexpected serious adverse reactions.

The economics also favour wider access. From randomisation to first treatment failure, participants on adalimumab incurred £1,117 in additional NHS costs, driven mainly by the drug itself, and the incremental cost-effectiveness ratio worked out at £2,320 per treatment failure avoided. Set against the economic burden of a treatment failure, which typically demands intensive therapy with additional imaging, high-dose steroids, immunomodulatory drugs, intravitreal injections and frequent monitoring, alongside productivity losses and informal care, the investigators argue this represents good value for money. A recent systematic review reported annual direct medical costs of non-infectious uveitis ranging from $16,428 to $134,135 per patient in 2023 US dollars, rising more than fourfold in those who become blind, providing context for the economic weight of preventing relapse. A full cost-utility analysis incorporating quality-adjusted life years is still to come from the trial.

The trial was not without limitations. Recruitment fell short of the target of 174 randomised participants, largely because the COVID-19 pandemic delayed the start and hospitals later prioritised clinical backlogs over research, and recruitment had to stop early when the placebo pens neared expiry on 31 January 2025 and the manufacturer could not extend their shelf life or supply new stock. Participants then transitioned into an ongoing open-label extension, which should establish the durability of response and longer-term safety. Even so, the message is clear: adalimumab can be used effectively and safely as an add-on therapy for a substantially broader population of patients with non-infectious uveitis than current guidance recognises, and the authors argue the NICE recommendation should now be reviewed. Roughly 30 percent of treated patients still fail within a year, however, highlighting a continuing unmet need for additional and complementary treatments for those whose disease remains refractory even to TNFα blockade.

Subject of Research: Efficacy and cost-effectiveness of adalimumab as add-on therapy for non-infectious uveitis in the ASTUTE randomised controlled trial

Article Title: Adalimumab versus placebo as add-on to standard therapy for non-infectious uveitis in the United Kingdom: the ASTUTE randomised controlled trial with treatment run-in

Article References: Dick, A. D., Reeves, B. C., Beare, N. A., Lui, M., Pike, K., Baos, S., Culliford, L., Zhu, X., Wordsworth, S., Folkard, A., Lanyon, K., Koleva-Kolarova, R., Brierley, R. C., Peto, T., Madhusudhan, S., Sharma, S. M., Epps, S., Naruganahalli, K., Clark, N., … Hamill, B. (2026). Adalimumab versus placebo as add-on to standard therapy for non-infectious uveitis in the United Kingdom: the ASTUTE randomised controlled trial with treatment run-in. eClinicalMedicine, 101, Article 104240. https://doi.org/10.1016/j.eclinm.2026.104240

Image Credits: AI Generated

DOI: Not provided

Keywords: adalimumab, non-infectious uveitis, randomised controlled trial, TNF-alpha inhibitor, biosimilar, corticosteroid sparing, NICE guidelines, treatment failure, macular oedema, ophthalmology, cost-effectiveness, immunomodulatory therapy

Trastuzumab, marketed originally as Herceptin by Roche, is a recombinant humanized monoclonal antibody that targets the extracellular domain of HER2, a transmembrane tyrosine kinase receptor amplified or overexpressed in 15 to 30 percent of breast cancers. That molecular abnormality historically signaled aggressive disease and poor prognosis, but trastuzumab changed the trajectory of the illness. Approved by the US Food and Drug Administration in 1998 as the first targeted therapy for HER2-positive metastatic breast cancer, the antibody, when combined with chemotherapy, improves overall survival by roughly one third in patients with early disease. Breast cancer itself remains the most commonly diagnosed cancer in women worldwide, with more than 2.3 million new cases and 666,000 deaths recorded in 2022, which makes reliable, affordable access to this therapy a global health priority.

The problem is cost. Biologic medicines such as trastuzumab are produced in living cells and are far more expensive to manufacture than small-molecule pills, a barrier that limits access for many patients, particularly in developing countries. After the patent on reference trastuzumab expired, several biosimilars were developed and approved by the FDA and the EMA. Unlike generic versions of chemical drugs, which can be shown to be identical through simple chemical analysis, biosimilars must demonstrate that they are highly similar in structure and function and that any differences carry no clinically meaningful consequences. That is where equivalence trials such as this one, known as study EGC002, come in.

The trial recruited women aged 18 to 65 with primary, operable, histologically confirmed HER2-positive early breast cancer, defined by a tumor larger than two centimeters with no metastases beyond the axillary lymph nodes. All participants first received four cycles of anthracycline-based chemotherapy with epirubicin and cyclophosphamide. They were then randomized one to one to receive either EG12014 or reference trastuzumab alongside paclitaxel, with the antibody given as an 8 mg/kg loading dose followed by 6 mg/kg maintenance infusions every three weeks. After surgery, patients continued adjuvant therapy to complete twelve months of trastuzumab treatment. Crucially, patients who had received the reference drug were rerandomized after surgery to either stay on it or switch to the biosimilar, creating a dedicated switch arm of 188 patients.

The primary endpoint was pathological complete response, or pCR, assessed by a central laboratory blinded to treatment assignment. This measure, defined as the absence of residual invasive cancer in the resected breast specimen and all sampled lymph nodes regardless of residual ductal carcinoma in situ, is endorsed by the FDA as a valid endpoint for neoadjuvant trials in high-risk early breast cancer. The results were strikingly close: 47.2 percent of patients on EG12014 achieved pCR compared with 47.8 percent on reference trastuzumab. The risk difference was minus 0.004, with a 95 percent confidence interval of minus 0.072 to 0.065, falling entirely within the EMA’s predefined equivalence margin of minus 0.13 to 0.13. The risk ratio analysis, required by the FDA, produced a relative risk of 0.992 with a 90 percent confidence interval of 0.880 to 1.118, comfortably inside the margin of 0.741 to 1.349.

Secondary endpoints reinforced the picture of equivalence. Rates of pCR under alternative definitions, objective response before surgery, event-free survival, and overall survival were all comparable between the arms. Subgroup analyses by age, race, hormone receptor status, performance status, geographic region, and tumor stage were generally supportive, though the authors caution that some categories were too small for firm conclusions. The trial was powered at 95 percent for the primary risk-difference analysis, assuming a true pCR rate of 35 percent in each arm, giving the result substantial statistical credibility.

Safety data were equally reassuring. Treatment-emergent adverse events were overwhelmingly mild to moderate, and the most frequent events, including alopecia in roughly 85 to 88 percent of patients, nausea, asthenia, and neutropenia, reflect the known toxicity of the chemotherapy backbone rather than the antibody itself. Serious adverse events occurred at similar rates across arms, between 14.4 and 18.6 percent of patients, and were dominated by COVID-19 infections during the pandemic period. Nine deaths were recorded, four in the EG12014 arm and five in the reference arm, all judged unrelated to trastuzumab and mostly linked to metastasis of the underlying cancer. Only 2.5 percent of patients discontinued treatment because of adverse events, with decreased ejection fraction, a recognized cardiac risk of HER2 blockade, the most common reason.

Immunogenicity and pharmacokinetics completed the biosimilarity picture. De novo antidrug antibodies appeared in only 3.3 percent of the EG12014 group, 2.7 percent of the switch group, and 4.8 percent of the reference group, and no patient developed neutralizing antibodies. Serum drug concentrations were comparable at every measured time point, and a population pharmacokinetic analysis using identical two-compartment models for both products confirmed that baseline body weight was the sole significant predictor of drug exposure in both arms. Importantly, the 188 patients who switched from reference trastuzumab to EG12014 after surgery showed no change in safety, immunogenicity, or drug levels, a finding that carries practical weight for health systems that may substitute biosimilars mid-treatment. Only one other trastuzumab biosimilar program, ABP 980, has incorporated a similar switch design into its pivotal trial.

The study weathered an extraordinary real-world stress test: the COVID-19 pandemic struck while enrollment was still underway, with the last patient randomized on March 24, 2020. Eighty-four infections were reported among participants, and some patients experienced delays in surgery or treatment, but these disruptions affected both arms similarly and did not alter the equivalence conclusion. The authors also acknowledge limitations, including a predominantly White, European cohort and the exclusion of male patients, whose breast cancer is rare. They note that current standards of care increasingly pair trastuzumab with a second HER2-targeting drug, pertuzumab, and suggest EG12014 could serve as the trastuzumab component in such combinations. With analytical comparability, Phase I bioequivalence data, and now Phase III clinical equivalence all aligned, EG12014 stands as a fully validated alternative, one that regulators hope will stimulate price competition, ease pressure on health systems, and extend life-saving targeted therapy to more of the millions of women diagnosed with breast cancer each year.

Subject of Research: Clinical equivalence of the trastuzumab biosimilar EG12014 with reference trastuzumab in HER2-positive early breast cancer

Article Title: Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized Study

Article References: Huang, C.-S., Dzagnidze, G., Grohmann-Izay, B., Liu, L.-C., Llinás-Quintero, N., Lin, A.-N., Mishra, A. K., Pominchuk, D., Prokharau, A., Rapoport, B. L., Semiglazov, V., Tseng, L.-M., Ruiz, E. Y., & Loibl, S. (2026). Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized Study. Advances in Therapy. https://doi.org/10.1007/s12325-026-03781-3

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03781-3

Keywords: trastuzumab, biosimilar, EG12014, HER2-positive breast cancer, Phase III trial, pathological complete response, neoadjuvant therapy, adjuvant therapy, immunogenicity, pharmacokinetics, EMA approval, early breast cancer